×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RANI – rani therapeutics holdings, inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RANI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
04:05 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
High
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
3/25
06:00 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Neutral
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
2/26
12:50 pm
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
Low
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
2/15
07:47 am
rani
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week [Yahoo! Finance]
Medium
Report
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week [Yahoo! Finance]
2/7
08:28 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
2/5
04:50 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC [Yahoo! Finance]
High
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC [Yahoo! Finance]
2/5
04:05 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Neutral
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
08:00 am
rani
rani therapeutics holdings, inc. - class a
MISS
Report
-4.9%
rani therapeutics holdings, inc. - class a
8/6/2024
04:05 pm
rani
rani therapeutics holdings, inc. - class a
BEAT
Report
-2.8%
rani therapeutics holdings, inc. - class a
5/6/2024
04:05 pm
rani
rani therapeutics holdings, inc. - class a
MISS
Report
-1.3%
rani therapeutics holdings, inc. - class a
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: